Novel FDA-approved zavegepant drug for treating migraine
Open Access
- 18 December 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (2) , 923-925
Abstract
Migraine is a complex neurological disorder characterized by recurring episodes of severe headaches. The pathophysiology of migraine involves abnormalities in neuronal networks, cortical spreading depression, and sensitization of trigeminovascular pathways. The global prevalence of migraine has increased substantially, warranting advancements in treatment strategies. A significant trigger in migraine pathophysiology is calcitonin gene-related peptide (CGRP). Several drugs, such as gepants and monoclonal antibodies (MABs) targeting CGRP or its receptor, have been developed to antagonize CGRP signaling. Zavegepant (Zavzpret), a novel CGRP receptor antagonist, has recently been approved by the FDA for the acute treatment of migraine. Clinical trials have demonstrated its efficacy in providing headache and symptom relief, with a statistically significant percentage of patients achieving freedom from headaches and most bothersome symptoms. Despite mild adverse effects, such as taste disorders and nausea, Zavzpret’s overall safety profile remains acceptable.Keywords
This publication has 16 references indexed in Scilit:
- Global, regional, and national burden of migraine in 204 countries and territories, 1990 to 2019Pain, 2021
- Migraine Aura: Updates in Pathophysiology and ManagementCurrent Neurology and Neuroscience Reports, 2020
- Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targetingExpert Opinion on Therapeutic Targets, 2020
- Migraine and the trigeminovascular system—40 years and countingThe Lancet Neurology, 2019
- Role of CGRP in Migraine2019
- MigraineAnnals of Internal Medicine, 2017
- CGRP and its receptorsHeadache: The Journal of Head and Face Pain, 2017
- Migraine biomarkers in cerebrospinal fluid: A systematic review and meta-analysisCephalalgia, 2016
- Premonitory and nonheadache symptoms induced by CGRP and PACAP38 in patients with migrainePain, 2016
- Vasoactive peptide release in the extracerebral circulation of humans during migraine headacheAnnals of Neurology, 1990